Ordering Recommendation

Use to detect drug exposure from among a targeted list of prescriptions, over-the-counter medications, and illicit drugs; for a complete list of drugs and drug metabolites detected, refer to Additional Technical Information. Not recommended to determine medication compliance or to assess for undisclosed drug/substance use in the context of pain management, substance use disorder treatment, or any other pharmacotherapies involving controlled substances.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Random urine with no additives.

Specimen Preparation

Transport 4 mL urine. (Min: 2 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Specimens exposed to repeated freeze/thaw cycles.

Remarks
Stability

Ambient: 1 days; Refrigerated: 2 weeks; Frozen: 2 months

Methodology

Qualitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Mon, Fri

Reported

1-8 days

Reference Interval

By Report

Interpretive Data

The drug screen panel can detect 127 drugs and drug metabolites by LC-MS/MS. The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies within a drug class. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

This assay is for medical purposes only; not valid for forensic use.

For a complete list of drugs and drug metabolites detected, refer to Additional Technical Information.

This test was developed, and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

If a specimen drug class is reported as positive, the test will report the confirmed component from the comprehensive drug class at no additional charge. (Classes include ARUP test codes 3005225, 3005226, 3005227, 3005228, 3005229, 3005230, 3005231, 3005232, 3005233, 3005234, 3005235, 3005236, 3005237, 3005238 or 3005239.)

Hotline History

N/A

CPT Codes

80323; 80325; 80329; 80334; 80337; 80338; 80341; 80344; 80347; 80348; 80353; 80354; 80355; 80356; 80357; 80359; 80360; 80361; 80363; 80365; 80366; 80368; 80370; 80371; 80372; 80373; 80377; 83992 (Alt code: G0482)

Components

Component Test Code* Component Chart Name LOINC
0090386 Creatinine, Urine 2161-8
3005017 Anticoagulants, Urine
3005018 Antihistamines, Urine
3005019 Cardiac, Urine
3005020 Anticonvulsants, Urine
3005021 Antidepressants, Urine 32136-4
3005022 Antipsychotics, Urine
3005023 Nicotine, Urine 12294-5
3005024 Opioids, Urine
3005025 Cough Suppressants, Urine 3539-4
3005026 NSAIDs, Urine
3005027 Benzodiazepines, Urine 3390-2
3005028 Muscle Relaxants, Urine
3005029 Sedative-Hypnotics, Urine
3005030 Stimulants, Urine
3005031 Antidiabetics, Urine
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Comprehensive drug screen
  • Drug Analysis
  • general toxicology
  • Multiple Drug Analysis
  • Tox Screen
Drug Profile, Expanded Targeted Panel by LC-MS/MS, Urine